By Adriano Marchese

AstraZeneca PLC (AZN.LN) said Friday that its Qtrilmet drug has been approved in the European Union to treat type-2 diabetes.

The drug maker said that Qtrilmet, a modified-release tablet to improve glycaemic control in adults with type-2 diabetes, was approved by the European Commission, based on data from five Phase 3 trials.

The drug was approved in the U.S. in May under the name Qternmet XR.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

November 15, 2019 02:26 ET (07:26 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.